Literature DB >> 7049077

Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy.

C E van Rensburg, E M Gatner, F M Imkamp, R Anderson.   

Abstract

The effects of clofazimine on neutrophil activities such as random motility, migration to the leukoattractants endotoxin-activated serum and N-formyl-L-methionyl-L-leucyl-L-phenylalanine phagocytosis of Candida albicans, postphagocytic hexose-monophosphate shunt activity, and myeloperoxidase-mediated iodination and the effects of clofazimine on lymphocyte transformation to mitogens were assessed in vitro and after ingestion of the drug by normal individuals and patients with lepromatous leprosy. For in vitro studies, the concentration range of the drug investigated was 10(-6) M to 10(-2) M. for in vivo studies, subjects ingested 200 mg of clofazimine daily for a period of 5 days. At concentrations of 5 X 10(-6) M to 5 X 10(-3) M clofazimine caused a progressive dose-dependent inhibition of neutrophil motility without detectable effects on phagocytosis, postphagocytic hexose-monophosphate shunt activity, or myeloperoxidase-mediated iodination. Over the same concentration range, clofazimine inhibited lymphocyte transformation. The inhibitory effect on neutrophil motility was associated with a spontaneous stimulation of oxidative metabolism and could be prevented by coincubation of dapsone with clofazimine. after ingestion of clofazimine responsiveness of lymphocytes to mitogens was decreased in normal volunteers and leprosy patients: neutrophil motility in normal individuals was likewise inhibited.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049077      PMCID: PMC181995          DOI: 10.1128/AAC.21.5.693

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Defective leukotaxis in patients with lepromatous leprosy.

Authors:  P A Ward; S Goralnick; W E Bullock
Journal:  J Lab Clin Med       Date:  1976-06

2.  A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G.30320 (B663).

Authors:  F M Imkamp
Journal:  Lepr Rev       Date:  1968-07       Impact factor: 0.537

3.  Stimulation of macrophage phagocytosis by clofazimine.

Authors:  L Brandt; B Svensson
Journal:  Scand J Haematol       Date:  1973

4.  Forty-four months' experience in the treatment of leprosy with clofazimine (Lamprene (Geigy)).

Authors:  E J Schulz
Journal:  Lepr Rev       Date:  1971-09       Impact factor: 0.537

5.  In vivo effects of propranolol on some cellular and humoral immune functions in a group of patients with lepromatous leprosy.

Authors:  R Anderson; E M Gatner; F M Imkamp; S H Kok
Journal:  Lepr Rev       Date:  1980-06       Impact factor: 0.537

6.  The in vitro effects of propranolol and atenolol on neutrophil motility and post-phagocytic metabolic activity.

Authors:  R Anderson; A J van Rensburg
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

Review 7.  Lamprene (clofazimine) in leprosy. Basic information.

Authors:  S J Yawalkar; W Vischer
Journal:  Lepr Rev       Date:  1979-06       Impact factor: 0.537

8.  In vitro and in vivo stimulation of neutrophil migration and lymphocyte transformation by thiamine related to inhibition of the peroxidase/H2O2/halide system.

Authors:  A Theron; R Anderson; G Grabow; J L Meiring
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

9.  Polymorphonuclear cell function in the various polar types of leprosy and erythema nodosum leprosum.

Authors:  R Sher; R Anderson; A Glover; A A Wadee
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

10.  Myeloperoxidase-mediated iodination by granulocytes. Intracellular site of operation and some regulating factors.

Authors:  R K Root; T P Stossel
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

View more
  7 in total

1.  Prooxidative activities of 10 phenazine derivatives relative to that of clofazimine.

Authors:  B M Zeis; R Anderson; J F O'Sullivan
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

2.  Clofazimine Reduces the Survival of Salmonella enterica in Macrophages and Mice.

Authors:  Toni A Nagy; Amy L Crooks; Joaquin L J Quintana; Corrella S Detweiler
Journal:  ACS Infect Dis       Date:  2020-04-29       Impact factor: 5.084

3.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

4.  Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.

Authors:  Scott M Irwin; Veronica Gruppo; Elizabeth Brooks; Janet Gilliland; Michael Scherman; Matthew J Reichlen; Rachel Leistikow; Igor Kramnik; Eric L Nuermberger; Martin I Voskuil; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

5.  Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro.

Authors:  R Anderson
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

6.  Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni.

Authors:  Gordana Panic; Mireille Vargas; Ivan Scandale; Jennifer Keiser
Journal:  PLoS Negl Trop Dis       Date:  2015-07-31

Review 7.  Multitarget Approaches against Multiresistant Superbugs.

Authors:  Declan Alan Gray; Michaela Wenzel
Journal:  ACS Infect Dis       Date:  2020-03-19       Impact factor: 5.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.